Reducing the antigen prevalence target threshold for stopping and restarting mass drug administration for lymphatic filariasis elimination: a model-based cost-effectiveness simulation in Tanzania, India and Haiti
<p><b>Background</b></p> The Global Programme to Eliminate Lymphatic Filariasis (GPELF) aims to reduce and maintain infection levels through mass drug administration (MDA), but there is evidence of ongoing transmission after MDA in areas where Culex mosquitoes are the main tr...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Oxford University Press
2024
|
| _version_ | 1811141274194935808 |
|---|---|
| author | Antony Oliver, MC Graham, M Gass, KM Medley, GF Clark, J Davis, EL Reimer, LJ King, JD Pouwels, KB Hollingsworth, TD |
| author_facet | Antony Oliver, MC Graham, M Gass, KM Medley, GF Clark, J Davis, EL Reimer, LJ King, JD Pouwels, KB Hollingsworth, TD |
| author_sort | Antony Oliver, MC |
| collection | OXFORD |
| description | <p><b>Background</b></p>
The Global Programme to Eliminate Lymphatic Filariasis (GPELF) aims to reduce and maintain infection levels through mass drug administration (MDA), but there is evidence of ongoing transmission after MDA in areas where Culex mosquitoes are the main transmission vector, suggesting that a more stringent criterion is required for MDA decision making in these settings.
<p><b>Methods</b></p>
We use a transmission model to investigate how a lower prevalence threshold (<1% antigenemia [Ag] prevalence compared with <2% Ag prevalence) for MDA decision making would affect the probability of local elimination, health outcomes, the number of MDA rounds, including restarts, and program costs associated with MDA and surveys across different scenarios. To determine the cost-effectiveness of switching to a lower threshold, we simulated 65% and 80% MDA coverage of the total population for different willingness to pay per disability-adjusted life-year averted for India (US dollars 446.07), Tanzania (US dollars 389.83), and Haiti (US dollars 219.84).
<p><b>Results</b></p>
Our results suggest that with a lower Ag threshold, there is a small proportion of simulations where extra rounds are required to reach the target, but this also reduces the need to restart MDA later in the program. For 80% coverage, the lower threshold is cost-effective across all baseline prevalences for India, Tanzania, and Haiti. For 65% MDA coverage, the lower threshold is not cost-effective due to additional MDA rounds, although it increases the probability of local elimination. Valuing the benefits of elimination to align with the GPELF goals, we find that a willingness to pay per capita government expenditure of approximately US dollars 1000–4000 for 1% increase in the probability of local elimination would be required to make a lower threshold cost-effective.
<p><b>Conclusions</b></p>
Lower Ag thresholds for stopping MDAs generally mean a higher probability of local elimination, reducing long-term costs and health impacts. However, they may also lead to an increased number of MDA rounds required to reach the lower threshold and, therefore, increased short-term costs. Collectively, our analyses highlight that lower target Ag thresholds have the potential to assist programs in achieving lymphatic filariasis goals. |
| first_indexed | 2024-04-09T03:58:07Z |
| format | Journal article |
| id | oxford-uuid:90518a84-df77-4345-bb96-4a446bb497a1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:35:16Z |
| publishDate | 2024 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:90518a84-df77-4345-bb96-4a446bb497a12024-09-16T12:47:09ZReducing the antigen prevalence target threshold for stopping and restarting mass drug administration for lymphatic filariasis elimination: a model-based cost-effectiveness simulation in Tanzania, India and HaitiJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:90518a84-df77-4345-bb96-4a446bb497a1EnglishSymplectic ElementsOxford University Press2024Antony Oliver, MCGraham, MGass, KMMedley, GFClark, JDavis, ELReimer, LJKing, JDPouwels, KBHollingsworth, TD<p><b>Background</b></p> The Global Programme to Eliminate Lymphatic Filariasis (GPELF) aims to reduce and maintain infection levels through mass drug administration (MDA), but there is evidence of ongoing transmission after MDA in areas where Culex mosquitoes are the main transmission vector, suggesting that a more stringent criterion is required for MDA decision making in these settings. <p><b>Methods</b></p> We use a transmission model to investigate how a lower prevalence threshold (<1% antigenemia [Ag] prevalence compared with <2% Ag prevalence) for MDA decision making would affect the probability of local elimination, health outcomes, the number of MDA rounds, including restarts, and program costs associated with MDA and surveys across different scenarios. To determine the cost-effectiveness of switching to a lower threshold, we simulated 65% and 80% MDA coverage of the total population for different willingness to pay per disability-adjusted life-year averted for India (US dollars 446.07), Tanzania (US dollars 389.83), and Haiti (US dollars 219.84). <p><b>Results</b></p> Our results suggest that with a lower Ag threshold, there is a small proportion of simulations where extra rounds are required to reach the target, but this also reduces the need to restart MDA later in the program. For 80% coverage, the lower threshold is cost-effective across all baseline prevalences for India, Tanzania, and Haiti. For 65% MDA coverage, the lower threshold is not cost-effective due to additional MDA rounds, although it increases the probability of local elimination. Valuing the benefits of elimination to align with the GPELF goals, we find that a willingness to pay per capita government expenditure of approximately US dollars 1000–4000 for 1% increase in the probability of local elimination would be required to make a lower threshold cost-effective. <p><b>Conclusions</b></p> Lower Ag thresholds for stopping MDAs generally mean a higher probability of local elimination, reducing long-term costs and health impacts. However, they may also lead to an increased number of MDA rounds required to reach the lower threshold and, therefore, increased short-term costs. Collectively, our analyses highlight that lower target Ag thresholds have the potential to assist programs in achieving lymphatic filariasis goals. |
| spellingShingle | Antony Oliver, MC Graham, M Gass, KM Medley, GF Clark, J Davis, EL Reimer, LJ King, JD Pouwels, KB Hollingsworth, TD Reducing the antigen prevalence target threshold for stopping and restarting mass drug administration for lymphatic filariasis elimination: a model-based cost-effectiveness simulation in Tanzania, India and Haiti |
| title | Reducing the antigen prevalence target threshold for stopping and restarting mass drug administration for lymphatic filariasis elimination: a model-based cost-effectiveness simulation in Tanzania, India and Haiti |
| title_full | Reducing the antigen prevalence target threshold for stopping and restarting mass drug administration for lymphatic filariasis elimination: a model-based cost-effectiveness simulation in Tanzania, India and Haiti |
| title_fullStr | Reducing the antigen prevalence target threshold for stopping and restarting mass drug administration for lymphatic filariasis elimination: a model-based cost-effectiveness simulation in Tanzania, India and Haiti |
| title_full_unstemmed | Reducing the antigen prevalence target threshold for stopping and restarting mass drug administration for lymphatic filariasis elimination: a model-based cost-effectiveness simulation in Tanzania, India and Haiti |
| title_short | Reducing the antigen prevalence target threshold for stopping and restarting mass drug administration for lymphatic filariasis elimination: a model-based cost-effectiveness simulation in Tanzania, India and Haiti |
| title_sort | reducing the antigen prevalence target threshold for stopping and restarting mass drug administration for lymphatic filariasis elimination a model based cost effectiveness simulation in tanzania india and haiti |
| work_keys_str_mv | AT antonyolivermc reducingtheantigenprevalencetargetthresholdforstoppingandrestartingmassdrugadministrationforlymphaticfilariasiseliminationamodelbasedcosteffectivenesssimulationintanzaniaindiaandhaiti AT grahamm reducingtheantigenprevalencetargetthresholdforstoppingandrestartingmassdrugadministrationforlymphaticfilariasiseliminationamodelbasedcosteffectivenesssimulationintanzaniaindiaandhaiti AT gasskm reducingtheantigenprevalencetargetthresholdforstoppingandrestartingmassdrugadministrationforlymphaticfilariasiseliminationamodelbasedcosteffectivenesssimulationintanzaniaindiaandhaiti AT medleygf reducingtheantigenprevalencetargetthresholdforstoppingandrestartingmassdrugadministrationforlymphaticfilariasiseliminationamodelbasedcosteffectivenesssimulationintanzaniaindiaandhaiti AT clarkj reducingtheantigenprevalencetargetthresholdforstoppingandrestartingmassdrugadministrationforlymphaticfilariasiseliminationamodelbasedcosteffectivenesssimulationintanzaniaindiaandhaiti AT davisel reducingtheantigenprevalencetargetthresholdforstoppingandrestartingmassdrugadministrationforlymphaticfilariasiseliminationamodelbasedcosteffectivenesssimulationintanzaniaindiaandhaiti AT reimerlj reducingtheantigenprevalencetargetthresholdforstoppingandrestartingmassdrugadministrationforlymphaticfilariasiseliminationamodelbasedcosteffectivenesssimulationintanzaniaindiaandhaiti AT kingjd reducingtheantigenprevalencetargetthresholdforstoppingandrestartingmassdrugadministrationforlymphaticfilariasiseliminationamodelbasedcosteffectivenesssimulationintanzaniaindiaandhaiti AT pouwelskb reducingtheantigenprevalencetargetthresholdforstoppingandrestartingmassdrugadministrationforlymphaticfilariasiseliminationamodelbasedcosteffectivenesssimulationintanzaniaindiaandhaiti AT hollingsworthtd reducingtheantigenprevalencetargetthresholdforstoppingandrestartingmassdrugadministrationforlymphaticfilariasiseliminationamodelbasedcosteffectivenesssimulationintanzaniaindiaandhaiti |